Literature DB >> 14593719

p27kip1 contributions to cancer.

Richard Seonghun Nho1, Robert J Sheaff.   

Abstract

Deregulation of the tumor suppressor p27kip1 (p27) has been implicated in a variety of human cancers, suggesting it might be a viable therapeutic target. Developing p27-specific intervention strategies requires understanding its role and regulation in normal and pathologic states. Although p27 has been extensively characterized as an inhibitor of cyclin-dependent kinases, disruption of this function is inadequate to explain its role in tumorigenesis. A more comprehensive understanding of p27 biology would facilitate development of therapeutic responses to p27 disruption in human cancers.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14593719

Source DB:  PubMed          Journal:  Prog Cell Cycle Res        ISSN： 1087-2957


  9 in total

1.  Effect of p27(KIP1) on cell cycle and apoptosis in gastric cancer cells.

Authors:  Jian-Yong Zheng; Wei-Zhong Wang; Kai-Zong Li; Wen-Xian Guan; Wei Yan
Journal:  World J Gastroenterol       Date:  2005-12-07       Impact factor: 5.742

2.  Spy1 is frequently overexpressed in malignant gliomas and critically regulates the proliferation of glioma cells.

Authors:  Li Zhang; Aiguo Shen; Qing Ke; Wei Zhao; Meijuan Yan; Chun Cheng
Journal:  J Mol Neurosci       Date:  2012-03-25       Impact factor: 3.444

3.  Effect of the cyclin-dependent kinases inhibitor p27 on resistance of ovarian cancer multicellular spheroids to anticancer chemotherapy.

Authors:  Hui Xing; Shixuan Wang; Keqin Hu; Wenming Tao; Jing Li; Qinglai Gao; Xiaokui Yang; Danhui Weng; Yunpin Lu; Ding Ma
Journal:  J Cancer Res Clin Oncol       Date:  2005-05-28       Impact factor: 4.553

4.  Regulation of vascular smooth muscle proliferation by heparin: inhibition of cyclin-dependent kinase 2 activity by p27(kip1).

Authors:  Stephen Fasciano; Rekha C Patel; Indhira Handy; Chandrashekhar V Patel
Journal:  J Biol Chem       Date:  2005-02-24       Impact factor: 5.157

5.  PAI-1 leads to G1-phase cell-cycle progression through cyclin D3/cdk4/6 upregulation.

Authors:  Evan Gomes Giacoia; Makito Miyake; Adrienne Lawton; Steve Goodison; Charles J Rosser
Journal:  Mol Cancer Res       Date:  2014-01-24       Impact factor: 5.852

6.  Over-expression of BMPR-IB reduces the malignancy of glioblastoma cells by upregulation of p21 and p27Kip1.

Authors:  Shuang Liu; Feng Yin; Wenhong Fan; Shuwei Wang; Xin-ru Guo; Jian-ning Zhang; Zeng-min Tian; Ming Fan
Journal:  J Exp Clin Cancer Res       Date:  2012-05-31

7.  Ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) is a potential tumour suppressor in prostate cancer and is frequently silenced by promoter methylation.

Authors:  Ramesh Ummanni; Edgar Jost; Melanie Braig; Frithjof Lohmann; Frederike Mundt; Christine Barett; Thorsten Schlomm; Guido Sauter; Tina Senff; Carsten Bokemeyer; Holger Sültmann; Catherine Meyer-Schwesinger; Tim H Brümmendorf; Stefan Balabanov
Journal:  Mol Cancer       Date:  2011-10-14       Impact factor: 27.401

8.  Akt1 sequentially phosphorylates p27kip1 within a conserved but non-canonical region.

Authors:  Lucas P Nacusi; Robert J Sheaff
Journal:  Cell Div       Date:  2006-06-16       Impact factor: 5.130

9.  Upregulation of p27 and its inhibition of CDK2/cyclin E activity following DNA damage by a novel platinum agent are dependent on the expression of p21.

Authors:  G He; J Kuang; Z Huang; J Koomen; R Kobayashi; A R Khokhar; Z H Siddik
Journal:  Br J Cancer       Date:  2006-11-07       Impact factor: 7.640
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.